PubMedCrossRef 17. Mollevi DG, Serrano T, Ginesta MM, Valls J, Torras J, Navarro M, Ramos E, Germa JR, Jaurrieta E, Moreno V, et al.: Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection. Carcinogenesis 2007,28(6):1241–1246.PubMedCrossRef 18. Nash GM, Gimbel M, Shia J, Nathanson DR, Ndubuisi MI, Zeng ZS, Kemeny MK-4827 N, Paty PB: KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann Surg Oncol 2010,17(2):572–578.PubMedCrossRef 19. Sobrero A: Molecular

markers of Selleckchem MK 1775 chemotherapy in advanced colorectal cancer: back to square one. Eur J Cancer 2009,45(11):1902–1903.PubMedCrossRef 20. Koopman M, Venderbosch S, Nagtegaal ID, Van Krieken JH, Punt CJ: A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned? Eur J Cancer 2009,45(11):1935–1949.PubMedCrossRef 21. Bertolini F, Bengala C, Losi L, Pagano M, Iachetta F, Dealis C, Jovic G, Depenni R, Zironi S, Falchi AM, et al.: Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007,68(5):1455–1461.PubMedCrossRef 22. Terzi C, Canda AE, Sagol O, Atila K, Sonmez D, Fuzun M, Gorken IB, Oztop

I, Obuz F: Survivin, p53, and Ki-67 as predictors check details of histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiotherapy. Int J Colorectal Dis 2008,23(1):37–45.PubMedCrossRef 23. Zlobec I, Vuong T, Compton CC, Lugli A, Michel RP, Hayashi S, Jass JR: Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy. Br J Cancer 2008,98(2):450–456.PubMedCrossRef 24. Albanese I, Scibetta AG, Migliavacca M, Russo A, Bazan V, Tomasino RM, Colomba P, Tagliavia M, La Farina M: Heterogeneity

Lonafarnib within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. Biochem Biophys Res Commun 2004,325(3):784–791.PubMedCrossRef 25. Di Nicolantonio F, Mercer SJ, Knight LA, Gabriel FG, Whitehouse PA, Sharma S, Fernando A, Glaysher S, Di Palma S, Johnson P, et al.: Cancer cell adaptation to chemotherapy. BMC Cancer 2005, 5:78.PubMedCrossRef 26. Tominaga T, Iwahashi M, Takifuji K, Hotta T, Yokoyama S, Matsuda K, Higashiguchi T, Oku Y, Nasu T, Yamaue H: Combination of p53 codon 72 polymorphism and inactive p53 mutation predicts chemosensitivity to 5-fluorouracil in colorectal cancer. Int J Cancer 2010,126(7):1691–1701.PubMed 27. Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK: Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 2007,94(3):274–286.PubMedCrossRef 28. Panasiuk A, Dzieciol J, Panasiuk B, Prokopowicz D: Expression of p53, Bax and Bcl-2 proteins in hepatocytes in non-alcoholic fatty liver disease.